article thumbnail

Challenges in Testing for SARS-CoV-2 Among Patients Who Recovered From COVID-19

JAMA Internal Medicine

Among patients who have recovered from COVID-19, repeated testing for SARS-CoV-2 may be done weeks or months after infection either as part of routine screening (eg, screening nursing home personnel on a weekly basis to prevent transmission of infections to patients) or because of the development of symptoms that are worrisome for reinfection.

Nurses 76
article thumbnail

AI in pharma: Can it be used in DTC?

World of DTC Marketing

Measuring RNA, DNA quickly. In the call center AI constantly updates the data base in reflection to patient or HCP questions so that call center nurses have answers to the most likely questions. Precision medicine or next-generation sequencing helps in the faster discovery of drugs and tailored medication for individual patients. .

Doctors 164
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Investigators Discover Unique Immune Cells in Patients with Checkpoint Inhibitor-Induced Arthritis

The Pharma Data

Flow cytometry and RNA sequencing analysis demonstrated these cells to be both cytotoxic and actively proliferating. Furthermore, RNA sequencing suggested that these cells may respond to the immune-related protein interferon, but more research is needed to confirm the significance. www.hss.edu.

Nurses 52
article thumbnail

?5 Things You Need to Know from Our Recent Gene Therapy Webinar

Worldwide Clinical Trials

We’ve also seen a decrease in available research nurses, as they have had to be reassigned to COVID patients. The pandemic has had a lasting impact on the ability of sites to participate in trials, particularly in the US. We’ve seen resignations across the sites we work with, as medical staff seek employment where they can work remotely.

article thumbnail

Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19

Pfizer

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Drugs 99
article thumbnail

Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVIDâ„¢ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

article thumbnail

Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVIDâ„¢ to Help Combat COVID-19

Pfizer

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs.

Drugs 110